P16INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma [2]

Journal of Chemotherapy

Volumn 16, Issue 4, 2004, Pages 411-413

  Raspollini, M R ^a   Amunni, G ^a   Villanucci, A ^a   Baroni, G ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P16; RETINOBLASTOMA PROTEIN; PROTEIN P16INK4A; TUMOR MARKER;

ADULT; AGED; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR RESISTANCE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CHEMISTRY; HYSTERECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARIECTOMY; OVARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 3943060802     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.4.411     Document Type: Letter

References (13)

1. Di Saia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003; 90: S24-S32.
2. Kim CK, Choi EJ, Choi SH et al. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic non-viral vector, DDC. Ginecol Oncol 2003; 90: 265-272.
3. Modesitt SC, Ramirez P, Zu Z et al. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001; 7: 1765-1772.
4. INK4a more efficacious than p53 for treatment of ovarian carcinoma? Clin Cancer Res 2001; 7: 1487-1489.
5. Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug resistance in ovarian cancer. Cancer 1987; 60: 2075-2080.
6. INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56: 3415-3420.
7. INK4a in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-6011.
8. Raspollini MR, Amunni G, Villanucci A, et al. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas. J Chemother 2003; 15(4): 359-365.
9. Kusume T, Tsuda H, Kawabata M, et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999; 5: 4152-4157.
10. Leversha MA, Fielding P, Watson S et al. Expression of p53, pRb, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol 2003; 200(5): 610-619.
11. Wolf JK, Kim TE, Fightmaster D et al. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 1999, 73: 27-34.
12. Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectives of adenovirus vectors expressing cyclin kinase inhibitors p16, p18, p19, p21 and p27 in inducing cell cycle arrest, apoptosis, and inhibition of tumorigenicity. Oncogene 1999; 18: 1663-1676.
13. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996; 56: 3199-3202.